Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.71 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CDK1 | P06493 | 3/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | CDK4 | P11802 | 2/20 | 0.52 |
| ▸ | CDK7 | P50613 | 2/20 | 0.52 |
| ▸ | CDK9 | P50750 | 2/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCNH | P51946 | 1/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10244050 | 0.91 | SYK (0.61) | SYKMAPK8MAPK9ZAP70CDK1 | |
| SCHEMBL764198 | 0.88 | SYK (0.69) | SYKMAPK8MAPK9CA2 | |
| SCHEMBL762023 | 0.88 | SYK (0.74) | SYKMAPK8MAPK9 | |
| SCHEMBL19772865 | 0.87 | SYK (0.72) | SYKMAPK8MAPK9 | |
| SCHEMBL764195 | 0.85 | SYK (0.64) | SYKMAPK8MAPK9ZAP70CA2 | |
| SCHEMBL3170368 | 0.83 | MAPK8 (0.66) | SYKMAPK8MAPK9CDK1CDK2 | |
| SCHEMBL12904964 | 0.83 | SYK (0.62) | SYKMAPK8MAPK9ZAP70PTK2 | |
| SCHEMBL738444 | 0.83 | SYK (1.00) | SYK | |
| SCHEMBL763194 | 0.83 | SYK (0.62) | SYKMAPK8MAPK9CDK1CDK2 | |
| SCHEMBL15161209 | 0.82 | SYK (0.67) | SYKMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | SYK 1/4885MAPK8 420/4885MAPK9 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.